SCHEMBL965853

SCHEMBL965853

Cc1nn(C)c(-n2ccc3cc(Cl)ccc32)c1C=CC(=O)NS(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 8/20 0.43
MAPT P10636 1/20 0.43
NR2F2 P24468 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC1 Q13547 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
PTGFR P43088 2/20 0.37
PTGER2 P43116 2/20 0.37
HSD11B1 P28845 1/20 0.35
PTGER1 P34995 2/20 0.34
PTGER4 P35408 2/20 0.34
EDNRA P25101 2/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
PHGDH O43175 3/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL965851 1.00 PTGER3 (0.43) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL964233 0.93 PTGER3 (0.42) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL964235 0.93 PTGER3 (0.42) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL962598 0.89 PTGER3 (0.41) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL962596 0.89 PTGER3 (0.41) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL5111983 0.88 SMN1; SMN2 (0.41) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL5111968 0.88 SMN1; SMN2 (0.41) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL963423 0.88 FLT1 (0.41) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL965317 0.88 PTGER3 (0.40) PTGER3MAPTNR2F2HTTSMN1; SMN2
SCHEMBL965316 0.88 PTGER3 (0.40) PTGER3MAPTNR2F2HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 PTGER3 2949/4885MAPT 4343/4885NR2F2 2010/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG PTGER3 456/4885MAPT 4720/4885NR2F2 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.